BTIG initiated coverage of Hims & Hers with a Buy rating and $35 price target. The firm says its likes Hims & Hers because of its “disruptive” business model approach that delivers health services to members through a non-traditional, direct-to-consumer, cash-pay approach. Demand for the company continues to be high, the home-grown electronic medical record seems comprehensive, and the business is well integrated with its 503A and 503B affiliated pharmacies, the analyst tells investors in a research note. BTIG expects Hims’ revenue growth and demand for obesity health products to remain robust.
previous post